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Received December 27, 2013; accepted July 4, 2014AbstractBackground: A rapid, reliable, and sufficiently accurate test for diagnosing Helicobacter pylori infection is required for screening dyspeptic
patients before a referral for endoscopy. The purpose of this article is two-fold: first, to evaluate the accuracy of a one-step H. pylori saliva
antigen (HPS) test; and second, to compare noninvasive and invasive H. pylori tests in Taiwanese population.
Methods: A total of 104 consecutive dyspeptic patients admitted for gastroenterology into the outpatient department underwent a one-step HPS
test, rapid urease test, histology, and 13C-urea breath test 13C-UBT (proto C-13 urea kit). The accuracy of the HPS test was compared with a gold
standard defined by at least two positive H. pylori test results from three H. pylori tests (histology, rapid urease test, and 13C-UBT).
Results: The 104 patients eligible for analysis (mean age: 58 years, range 22-87 years), 21 (20%) were gold standard positive. Among them, the
positive of the one-step H. pylori saliva Ag test, rapid urease test, 13C-UBT, histology were (52; 50%), (17; 16%), (27; 25%) and (22; 21%)
respectively. The sensitivity and specificity of the HPS tests, rapid urease test, 13C-UBTs, and histology were 71.43% and 55.42%, 76.19% and
98.80%, 100% and 92.77%, and 85.71% and 95.18%, respectively, relative to the gold standard. The one-step HPS test exhibited a sensitivity of
71.43%, nearly equivalent to that of the rapid urea test.
Conclusion: The one-step HPS test exhibited a high sensitivity and low specificity compared with the other tests, indicating that it is not
sufficiently accurate for use in a clinical setting for diagnosing H. pylori infection. However, the test is simple to use (requiring only a saliva
sample), inexpensive, and noninvasive in its application, and thus appealing for use in population-based prevalence surveys of the epidemiology
of H. pylori infection.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Helicobacter pylori infection is common worldwide. The
prevalence of H. pylori among developing countries, devel-
oped countries, and Taiwan are approximately 80e90%, 50%,Conflicts of interest: The authors declare that there are no conflicts of interest
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1726-4901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Assand 55%, respectively.1 H. pylori is a Gram-negative, micro-
aerophilic bacterium found in the stomach. It was identified in
1982 by Barry Marshall and Robin Warren, who observed that
it was present in patients with chronic gastritis and gastric
ulcers. H. pylori infection is a major factor in the etiology of
peptic ulcer disease, chronic gastritis, gastric cancer, and
gastric mucosa-associated lymphoid tissue lymphoma.
Because of its widespread prevalence and clinical significance,
H. pylori infection constitutes a major public health concern.2
Diagnostic methods for H. pylori infection have generally
been divided into direct (invasive) and indirect (noninvasive)
tests.3 The invasive method is based on directly identifying theociation. All rights reserved.
97B.-L. Yang et al. / Journal of the Chinese Medical Association 78 (2015) 96e100microorganism by studying samples obtained using gastric
biopsy. Noninvasive tests can be performed on serum,4 saliva,5
stool,6 or breath sample.7 When patients are screened for the
presence of the microorganism prior to referral for upper
gastrointestinal endoscopy, this allows resources to be directed
toward patients who are likely to develop severe pathology. It
has been shown that H. pylori status as determined by serology
predicts endoscopic findings more accurately than formal
questioning.8 In this study, we have proposed a novel, rapid,
reliable, and accurate test for diagnosing H. pylori infection
which could be efficacious for screening dyspeptic patients
prior to a referral for endoscopy.8
2. Methods
This study compared the performance of several candidate
screening tests, including the noninvasive one-step H. pylori
saliva antigen (HPS) Test (Ameritek, Everett, WA, USA), the
13C-urea breath test (13C-UBT; proto C-13 urea kit, Synmosa
Biopharma Corporation, Taipei, Taiwan), and the invasive
histology and rapid urease test (HelicotecUT; Strong Biotech,
Taipei, Taiwan). Subsequently, the accuracy of the new one-
step H. pylori saliva Ag test was also evaluated.2.1. Study populationParticipants were selected from patients admitted for gas-
troenteropathy into the Outpatient Department at the Depart-
ment of Gastroenteropathy, Cheng-Hsin General Hospital, in
Taipei, Taiwan between June 1, 2012 and December 31, 2012.
A total of 140 gastroenteropathy OPD patients, aged 20e80
years and presenting with abdominal discomfort as well as
dyspeptic symptoms were admitted for upper gastrointestinal
panendoscopy.
The criteria applied for exclusion from the study included:
(1) the use of antimicrobials, proton-pump inhibitors (PPIs),
H2 blockers, and bismuth derivatives within 1 month before
the study; (2) previous upper digestive hemorrhages and
gastric cancer; and (3) presence of any underlying systemic
diseases such as heart disease, combined with ingesting anti-
platelet and anticoagulants.
The study followed the standards of the Declaration of
Helsinki and has been approved by the Institutional Review
Board (IRB) of Cheng-Hsin General Hospital [CHGH-IRB:
(298) 101-11-1]. As the dataset used in this study consists of
de-identified data from a retrospective cohort, written informed
consent from the patients receiving upper gastrointestinal
panendoscopy services was waived by the approval of the IRB.
During enrollment, patients had their medical histories
taken and charts reviewed in the endoscopy room of the
Department of Gastroenteropathy, Cheng-Hsin General Hos-
pital. This was undertaken to determine the participants'
medical history, such as peptic ulcer disease, heart disease,
previous H. pylori infection, and drug history, such as the use
of anticoagulants, antiplatelet, antibiotics, or PPIs.
Prior to each patient undergoing endoscopy, a well-trained
representative from the saliva test's company performed asaliva test as follows: No food or drink was allowed 1 hour
before the test. To perform the test, approximately 2e3 mL of
saliva were extracted from each participant and mixed with
6e8 drops of an extraction buffer. After mixing, a pipette was
used to transfer four drops of the mixture into the sample well
of the test cassette. As the test kit begins to work, a purple color
moves across the result window in the center of the test disk.
The results are observed within 5e30 minutes. The occurrence
of two bands (T band and C band) in the test and control zones
was positive for H. pylori. The occurrence of one band in the
control zone was negative for H. pylori. If there was no band in
the control zone (invalid result) the samples were retested.
After extracting saliva from the participants, a consultant
physician performed an endoscopy. Four antral mucosal bi-
opsy specimens were extracted from each patient. Three bi-
opsies obtained from around the antrum (of 4 quadrants)
within 3 cm of the pylorus were sent for histology. The
presence of H. pylori was determined by staining with he-
matoxylin and eosin. If no Helicobacter organisms were
observed, then a modified Giemsa stain was applied. The
remaining antral biopsy specimen was used for a slide biopsy
rapid urease test (HelicotecUT Biotech). The test was checked
30 minutes after insertion of the biopsy, and then reviewed at
24 hours, after which the result was recorded.
Immediately after the endoscopies, each participant un-
derwent the 13C-UBT.7 The patients were required to exhale
two breath samples into two individual sample bags [i.e., a
normal breath and a second breath after consuming a lemon-
flavored 13C-urea solution (PROTOC-13 urea kit)]. The
mechanism of the 13C-UBT is used to measure the urease
activity of H. pylori.7 The bacterium produces copious
amounts of urease, which breaks down the 13C-labeled urea to
produce labeled CO2 and ammonia. The CO2 is dissolved in
the blood stream and transported to the lungs for removal.
Exhaled CO2 was collected in a bag and then processed and
analyzed using the advanced Ap 2005 - 13C-Breath Gas
Analysis (Analytical Precision Limited, Windsor House
Northwich, Cheshire CW9 7TN), Isotope Ratio Mass Spec-
trometer.7 A quick report was generated in 7 minutes.2.2. Statistical analysisGold standard positives were defined as those with at least
two positive test results among the rapid slide biopsy urease
test, histology, and 13C-UBT. Gold standard negatives were
defined as those with negative results for all three tests (or 2
tests if the 13C-UBTwas not conducted).9 Performance of tests
in diagnosing H. pylori infection was examined by using area
under the receiver operator characteristic curves (AUROC),
which was expressed as plots of the test sensitivity vs. 1e
specificity. A significance level of 0.05 was used for all sta-
tistical calculations. Using the gold standard test as a refer-
ence, sensitivity, specificity, positive and negative predictive
values, and precisely associated 95% confidence intervals
(CIs) were calculated for the saliva test, rapid urease test, 13C-
UBT, and pathology of the participants.
Table 1
Characteristics of 104 patients enrolled in Cheng-Hsin Hospital undergoing
esophagogastroduodenoscopy between 2012/06 and 2012/12.
Characteristic % (n)
Mean age (min, max) 58 y (22, 87)
Sex (M/F) 49/61% (40/64)
Medical chart review
History of peptic ulcer disease 10% (11)
Previous EGD 29% (30)
Previous treated for H. pylori 5% (6)
Naïve patient 54% (57)
Endoscopic evaluation during EGD
Esophagitis 22% (23)
Hemorrhagic gastritis 26% (28)
Atrophic gastritis 4% (5)
Erosive gastritis 16% (17)
Superficial gastritis 7% (8)
Ulcers (gastric ulcer, duodenal ulcer) 20% (21)
Negative 1% (2)
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After excluding 36 patients because of recent consumption
of antiplatelet (n ¼ 11), antibiotics (n ¼ 9), PPIs (n ¼ 13), and
absence from the 13C-UBT (n ¼ 3), 104 patients were eligible
for analysis (Fig. 1). Table 1 shows the characteristics of the
104 patients who underwent endoscopy. The mean age of the
participants was 58 years, and 61% were female. Among the
104 participants, 21 (20%) were gold standard positives for the
one-step H. pylori saliva Ag test (n ¼ 52; 50%), rapid urease
test (n ¼ 17; 16%), 13C-UBT (n ¼ 27; 25%), and histology
(n ¼ 22; 21%); and 83 (80%) were gold standard negatives
(Table 2).
The sensitivity of the one-step saliva test in relation to the
invasive tests ranged from 71.43% to 85.7% (Table 3). The
one-step HPS test exhibited a sensitivity of 71.43%, nearly
equivalent to that of the rapid urease test.
Comparison of the AUROC of the four tests (HPS, Heli-
cotecUT test, 13C-UBT, and pathology) in relation to the gold
standard were 0.634 (95% CI, 0.504e0.764), 0.875 (95% CI
0.764e0.986), 0.964 (95% CI, 0.930e0.998), and 0.904 (95%
CI, 0.813e0.996), respectively, with p  0.05 (Table S1). In
relation to AUROC, 13C-UBT (AUROC 0.964) is best for
testing diagnostic accuracy, although the HPS test (AUROC
0.634) is also sufficient. From this result, we could calculate
the minimal required sample size as 144.
4. Discussion
Diagnostic methods for H. pylori infection have generally
been divided into direct (invasive) and indirect (noninvasive)
tests.7 The invasive test is based on directly identifying the
microorganism by studying samples obtained using gastric
biopsy.3 Noninvasive tests can be performed on serum, saliva,
stool, or breath samples.
The choice of a diagnostic test should depend on the clin-
ical circumstances, the pretest probability of infection, sensi-
tivity and specificity of the test (or more correctly, the
likelihood ratio of a positive and negative test), the cost
effectiveness of the testing strategy, and the availability of theFig. 1. Flow chart of the study.test.10 Certain clinical circumstances warrant invasive studies:
patients who have failed eradication therapy might require
culture and antimicrobial sensitivity testing to help determine
an appropriate regimen, and older patients presented with new
onset dyspepsia and those with “alarm” symptoms (such as
bleeding and weight loss) that raise concerns of malignancy.
Noninvasive protocols are preferred for epidemiological
studies and for young children.4,10,11 In addition to facilitating
epidemiological research, noninvasive H. pylori testing can be
successfully used for pre-endoscopic screening of patients
referred to a gastroenterology12 service for investigating
dyspepsia as well as therapeutic monitoring after eradication
therapy. Using noninvasive tests to screen young patients and
children4,10 who present with dyspepsia has been advocated on
the basis of a decrease in overall endoscopy workload and
resultant financial savings.12
Recently, some noninvasive methods of testing for H. pylori
have become available: (1) the 13C- or 14C-labeled UBT; (2)
serology (based on detection of a specific anti-H. pylori IgG
antibody in the patient's serum); and (3) H. pylori stool anti-
gens test. Several novel methods of detecting H. pylori have
recently been described and include detecting antibodies in
saliva and urine and detecting antigens in stool.13
That H. pylori can be transmitted by both oral to oral and
stomach to oral routes has been recognized since 1989 when
Shames et al14 first isolated H. pylori from the dental plaque of
patients with gastric diseases related to H. pylori infection.
Several studies have suggested that oral H. pylori is associated
with the presence of gastric H. pylori14,15 infection, andTable 2
Percent positive for Helicobacter pylori by test type among 104 patients
enrolled in Cheng-Hsin Hospital for H. pylori infection study,
JuneeDecember 2012.
Test type % of H. pylori positive (n)
Saliva antigen test 50 (52)
HelicotecUT test 16 (17)
Histology 21 (22)
13C-UBT 25 (27)
Gold standard 20 (21)
Table 3
Sensitivity and specificity of Helicobacter pylori tests in relation to gold
standard in 104 patients from Cheng-Hsin Hospital.
Positive,
n (%)
Sensitivity
(%)
Specificity
(%)
PPV (%) NPV (%)
Saliva antigen test 52 (50) 71.43 55.42 29.11 88.33
HelicotecUT test 17 (16) 76.43 98.8 94.1 94.3
13C-UBT 27 (25) 100 92.77 77.8 100
Histology 22 (21) 85.71 95.18 81.8 96.3
Gold standard 21 (20)
NPV ¼ negative predictive value; PPV ¼ positive predictive value;
UBT ¼ urea breath test.
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success rate of gastric H. pylori eradication than oral H. py-
lori-negative individuals.16,17
A search using PubMed found 305 articles that have
“Helicobacter pylori” and “saliva” in the title, 26 titles that
also include antigen in the title, and only three titles that are
about detection of oral H. pylori antigen in humans.
Namiot et al18 screened 155 patients with no history of H.
pylori infection and found that 65.6% were positive for H.
pylori in dental plaque using the Oxoid IDEA Hp StAR
amplified immunoassay test (which uses monoclonal anti-
bodies to detect fecal antigen).
Yee et al17 screened 201 participants; they were then
separated into UBTþ and UBT groups. They found that oral
screening test could identify persons with no symptoms but
with antigenic evidence of possible oral H. pylori infection
who are at risk for developing gastric disease. In Yee et al's17
experiment, the HPS test results were compared with the UBT,
serum antibody, campylobacter-like organism test, silver stain,
culture, and stool antigen test results. Oral antigen tests were
positive in 41 UBT people, indicating that they may have H.
pylori antigen in the mouth in the absence of disease.
Song and Li16 screened 391 patients with dyspepsia who
underwent gastroscopy and histopathological examination ofTable 4
The results based on Helicobacter pylori saliva antigen test.
Reference Patients
(number)
Tests Study design
Namiot et al18 155 H. pylori antigens in
supragingival plaque
Used the immu
of H. pylori an
H. pylori antig
no history of H
Yee et al17 201 HPS, UBT, serum antibody,
Campylobacter-like
organism test, silver stain, culture,
and stool antigen test
HPS results we
UBT, serum an
test, silver stai
Song and Li16 391 233 patients who were
13C-UBTþwere divided Into four
Treated with
O-Gþt (53) triple therapy
OþGþt (53) triple therapy
OþGþtm (65) triple therapy þ
OþGþtmp (62) triple therapy þ
G ¼ gastric test by UBT; HPS ¼ saliva H. pylori antigen test; O ¼ oral test by HPS;
therapy þ mouth rinse þ periodontal treatment; UBT ¼ C-13 urea breath test.gastric mucosa. To evaluate H. pylori in the oral cavity, the
authors used an HPS test based on detection of H. pylori an-
tigen in saliva using rapid immuneechromatographic assay.
For evaluation of H. pylori in stomach mucosa, the authors
used the 13C-UBT. The results showed that the eradication of
H. pylori in the mouth cavity using mouth rinse and peridental
treatment could kill the oral H. pylori and improve the erad-
ication rate of gastric H. pylori by triple therapy (Table
4).16e18
The accuracy of a test is crucial in diagnosing a condition
or assessing a marker for disease.15 A greater scope is possible
in the population-based setting to adjust for known test inac-
curacies in the reporting of rates and their comparisons.9 In
large-scale studies of H. pylori, the saliva-based test is a
particularly attractive alternative to serum-based tests because,
in addition to eliminating the need to employ trained personnel
to draw blood, saliva sampling might provide a better response
rate than serum sampling in studies using volunteers. Anti-
body levels persist in the blood for extended periods of time.
The persistent antibody causes increasingly frequent false
positive test rate.19 Serology has been the most widely used
test, but the sensitivity and specificity of this test is compar-
atively low. The UBT is the most accurate noninvasive test, but
is expensive and difficult to perform.7
This study provides essential information on the AUROC of
four tests commonly used in clinical practice for diagnosing H.
pylori infection. Clinicians use a variety of tests to diagnose H.
pylori infection in patients presented with abdominal symp-
toms. These data were used to compare the sensitivity, spec-
ificity, and AUROC of each test and gold standard test. We
evaluated the performance of H. pylori tests in a population of
Taiwanese adults by using various methods and evaluated the
AUROC of the new one-step HPS test.
In this study, we proposed a novel rapid, reliable, and ac-
curate test for diagnosing H. pylori infection required for
screening dyspeptic patients prior to a referral for endoscopy.Results
nological method (a kit for detection
tigens in stool samples.) to test
ens in supragingival plaque despite
. pylori infection
65.6% were positive for
H. pylori in dental plaque
re compared in parallel with the
tibody, Campylobacter-like organism
n, culture, and stool antigen test results
Oral antigen tests were positive
in 41 UBTe people, indicating
that they may have H. pylori
antigen in the mouth in the
absence of disease
Eradication rate of gastric H pylori
42 (93.3)
40 (78.4)
mouth rinse 54 (90.0)
mouth rinse þ periodontal treatment 54 (94.7)
t ¼ treated with triple therapy; tm ¼ triple therapy þ mouth rinse; tmp ¼ triple
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highly sensitive to H. pylori urease, developed to use saliva as
a specimen for detecting H. pylori colonization in the gas-
trological tract and oral cavity.17 The monoclonal antibody
used in the assay reacts with only H. pylori urease; thus, it has
a high sensitivity and specificity. The analytical sensitivity of
the test is 10 ng/mL of H. pylori urease.17 There was no
interference or cross reactivity with the other bacteria in the
oral cavity and there was statistical correlation between oral
antigen and serum antibody test results.
Our results showed that the positive rate of HPS was
71.43%, nearly equivalent to that of the saliva H. pylori test's
74.9% in Song and Li's study16 and demonstrating that the
mouth is another storage site for H. pylori. In this study, the
gastric H. pylori eradication rate in HPSþ positive patients
was lower than that in HPS patients (78.4% vs. 93.3%). The
test results of gastric and oral H. pylori were not consistent in
this study. Previous studies have shown that H. pylori does not
colonize in the mouth of a person with good oral hygiene (e.g.,
no periodontal disease, no gingival band, or plaque). In this
situation, the oral H. pylori titer is low and does not reach the
threshold of gastric H. pylori infection. Therefore, a saliva test
to detect gastric H. pylori infection would give negative re-
sults. For gastric H. pylori-positive patients with good oral
hygiene, although gastric H. pylori may be refluxed into the
mouth; the bacterium may not survive in the mouth.
In this study, the HPS test had a high sensitivity, which
enabled it to detect a low titer of H. pylori.17 Therefore, the
positive rate for oral H. pylori infection was higher than that
for gastric H. pylori infection.
The sensitivity of the one-step HPS test in relationship to
the invasive tests and the gold standard ranged from 72% to
88%. The one-step HPS test had exhibited a sensitivity of
71.43%, nearly equivalent to that of the rapid urea test. The
salivary assessment achieved a relatively high sensitivity and
low specificity, compared with the other tests, indicating that it
is not sufficiently accurate for use in a clinical setting for
diagnosing current H. pylori infection. However, because it is
easy to use (requiring only a saliva sample), inexpensive, and
noninvasive, it is attractive for use in population-based prev-
alence surveys for H. pylori infection. In addition, HPS can
diagnose oral H. pylori in individuals with no symptoms. It
further identified those with no symptoms but with antigenic
evidence of possible oral H. pylori infection who are thus at
risk for developing gastric disease and recurrence infec-
tion.16,17 It is a simple and rapid method to test for and
eliminate oral H. pylori. This method can be used to prove the
elimination of gastric H. pylori, and it is practical for use in
the clinical environment as well.16
There are certain limitations to our study. First, this study
included all outpatients who presented with epigastralgia;
thus, the prevalence of H. pylori was low. Second, the sample
size of this study was lower than the effective sample size.
Third, the HPS test achieved relatively high sensitivity and low
specificity. Nevertheless, further large population studies are
still needed to validate this result.Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jcma.2014.11.004.
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